A different combination approach consists in genetically fusing a full-length monoclonal antibody targeting the cancer cell, such as rituximab, with a more biological component represented by a TNF superfamily ligand, such as CD95L, in its full-length, or truncated form, or a fragment thereof, thus offering two approaches to kill cancer cells. Here, FASLG is linked to cancer.